Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: TradeOfTheDay who wrote (710)	11/12/1997 12:35:00 PM
From: Antonios Petropoulos	Read Replies (1) \| Respond to of 1605

Like I said i don't know.More time? That is what we were saying before the results were out.That we needed more time, now that we have the results we say again more time? maybe that is what people selling today didn't like. I am a bit frustrated because with all the news coverage yesterday and someone else mentioning that Wall Street Journal interviewd Vaso's CEO and USA Today interview Vaso officials. Despite that Vaso dropped like a rock today and instead of 3.75 we have 2.75! Still looking for an explanation... (unless people selling know some bad news that we don't)

To: TradeOfTheDay who wrote (710)	11/12/1997 1:49:00 PM
From: Harvey Barish	Read Replies (1) \| Respond to of 1605

Hi Bev: Thanks for your clear thinking. I agree completely with your assessment of VASO. This is a new protocol that just had its first real news announcement and a spectacular one at that. This one's a keeper.

To: TradeOfTheDay who wrote (710)	11/12/1997 6:17:00 PM
From: Fred Levine	Read Replies (1) \| Respond to of 1605

Bev--Your post was right on target. I have little to add except emphasize one of your points-- how market-driven medicine is now. There will be immediate circulation (pun intended) of the results to angina patients about EECP. They will pressure their insurance comapnies, who, in turn, will see the cost benefits. Right now, I am sure every one of the centers involved in the MUST-EECP study are getting many calls. The market must expand. Not to be cynical, but I am glad there are empirical data supporting EECP, because, unfortunately, people with angina will go after treatments of dubious efficacy. good investing--fred